The carbon footprint of pharmaceuticals for diabetes and cardiovascular diseases

First published: 09/01/2026

Last updated: 09/01/2026

Study Ongoing

Administrative details

EU PAS number

EUPAS1000000641

Study ID

1000000641

DARWIN EU® study

No

Study countries

Denmark

Study description

Objective: This scoping review aims to gather published knowledge about the carbon footprint of pharmaceuticals for diabetes (ATC A) and cardiovascular disease (ATC C, excluding C05A) reported in peer reviewed publications.

Purpose: To enhance the role health professionals, play in reducing the carbon footprint of the most prescribed pharmaceuticals globally.

Study status

Ongoing

Research institutions and networks

Institutions

University of Copenhagen

Bispebjerg and Frederiksberg Hospital

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Technical University of Denmark

Contact details

Study institution contact

Helena Hedegaard Udsen gjc187@alumni.ku.dk

Study contact

gjc187@alumni.ku.dk

Primary lead investigator

Helena Hedegaard Udsen

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 01/05/2025

Study start date

Planned: 01/06/2025

Actual: 01/06/2025

Data analysis start date

Planned: 01/09/2025

Date of final study report

Planned: 01/01/2026

Sources of funding

More details on funding

No funding was used

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Other

Study topic, other:

Carbon footprint

Study type:

Non-interventional study

Scope of the study:

Scoping review (including literature review)

Data collection methods:

No individual level data collected for the purpose of the study

Study design:

Scoping review with search in PubMed, Scopus, Embase and Web Of Science.

Main study objective:

Objective: This scoping review aims to gather published knowledge about the carbon footprint of pharmaceuticals for diabetes (ATC A) and cardiovascular disease (ATC C, excluding C05A) reported in peer reviewed publications.

Study Design

Non-interventional study design

Other

Non-interventional study design, other

Scoping review

Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(A10) DRUGS USED IN DIABETES

DRUGS USED IN DIABETES

(C) CARDIOVASCULAR SYSTEM

CARDIOVASCULAR SYSTEM

Additional medical condition(s)

ATC group A10 and C (excluding C05A)

Study design details

Setting

Inclusion

- Language: English

- Peer reviewed original article.

- A carbon footprint reported on a pharmaceutical.

- Pharmaceutical from the pharmacological group ATC A10 (antidiabetic pharmaceutical) or ATC C (cardiovascular pharmaceutical) excluding ATC C05A (pharmaceuticals for hemorrhiods and anal fissures).

- Reporting of the absolute number of the carbon footprint e.g. in a unit measurement of CO2-equivalent.

- Articles published before June 1st, 2025.

Exclusion

- Carbon footprint only on packaging or transportation of the pharmaceutical.

- Carbon footprint only reported in percentage without information that enable absolute calculation of carbon footprint.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s), other

PubMed, Web of Science, Scopus and Embase

Data sources (types)

Published literature

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

Not applicable